Introduction: The appreciable growth in pharmaceutical expenditure has resulted in multiple initiatives across Europe to lower generic prices and enhance their utilisation. However, considerable variation in their use and...
Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are effectiveness, safety and/ or budget concerns. Dabigatran, a new oral anticoagulant for...
Jihn Kim, Yannis Semertzidis and Shinji Tsujikawa
February 28, 2015
Department of Neurology, The University of Texas Southwestern Medical Centre
Frontiers Review Editor
Michigan State University
East Lansing, USA
© 2007 -
Frontiers Media S.A. All Rights Reserved